McKesson signed USD 5.8 billion deal: Barclays targets McKesson stock at USD 1,000.00

Published on 10/09/2026 at 16:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock costs EUR 832.50 on October 9, 2026 versus EUR 829.80. Revenue hit USD 105.38 billion in fiscal 2027 first quarter, up 7.70 percent.

Key points in brief

McKesson signed a USD 5.8 billion agreement with CD&R to acquire Option Care Health on October 6, 2026.
McKesson will invest USD 1.4 billion for an approximately 49 percent stake, while CD&R will hold 51 percent.
Fiscal 2027 first-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year.
McKesson stock was trading at EUR 832.50 at Lang & Schwarz on October 9, 2026, plus 0.33 percent versus the prior close.

Comic-Illustration im Pop-Art-Stil zeigt Apotheker der Kundin eine Tüte überreicht — Pop-Art-Comic-Szene einer Apothekenübergabe visualisiert farbenfroh das Kerngeschäft von McKesson Corporation ISIN US58155Q1031 heiter und freundlich, Illustration mit AI erstellt.

McKesson (ISIN US58155Q1031) was trading at EUR 832.50 at Lang & Schwarz on October 9, 2026, with the euro quote up 0.33 percent versus the prior close of EUR 829.80. On October 6, 2026, McKesson signed an agreement with CD&R to acquire Option Care Health for a USD 5.8 billion enterprise value, while Barclays had raised its McKesson target from USD 925.00 to USD 1,000.00 on August 19, 2026.

Option Care adds specialty care

According to McKesson on October 6, 2026, McKesson will invest USD 1.4 billion for a 49 percent minority interest in Option Care Health. CD&R will hold 51 percent, and the transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals.

The structure gives McKesson exposure to home and alternate-site infusion services without taking majority control at closing. The agreement also creates a framework for McKesson to acquire CD&R's interest later, subject to specified conditions.

What does the deal add?

The strategic case is visible in McKesson's recent operating figures. MarketBeat reported on August 5, 2026, that fiscal 2027 first-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year, while earnings per share came in at USD 9.93 versus USD 9.56 consensus.

MarketBeat also reported on October 8, 2026, that 18 brokerages had a consensus 12-month target of USD 973.19, with 14 buy ratings and four holds. Barclays' USD 1,000.00 target is 7.50 percent above the USD 930.16 NYSE quote supplied for October 9, 2026, using the same currency.

Three strategic steps in 2026

On September 9, 2026, McKesson agreed to acquire Precision Medicine Group for USD 2.25 billion, according to Outsource Accelerator. On October 1, 2026, McKesson extended its CVS Health distribution arrangement through June 2032 and reaffirmed fiscal 2027 adjusted earnings per share guidance of USD 44.20 to USD 45.00, according to StockTitan. On October 6, 2026, the Option Care agreement set the current capital-allocation direction.

Next dates for McKesson

McKesson's next scheduled reporting date is November 4, 2026, when it is expected to release fiscal 2027 second-quarter results after the market close, according to StockAnalysis. The Option Care transaction is targeted for completion in the first half of 2027, subject to the stated approvals.

McKesson stock holds above prior close

At Lang & Schwarz, McKesson stock was trading at EUR 832.50 on October 9, 2026 at 4:08 p.m. CEST, plus 0.33 percent versus the Lang & Schwarz prior close of EUR 829.80 on October 8, 2026. The NYSE 52-week range was USD 723.68 to USD 999.00, while market capitalization stood at USD 108.9 billion as of October 9, 2026. The further course of trading is shown by the continuously updated real-time quote of McKesson stock.